Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
Public ClinicalTrials.gov record NCT04488003. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This BVD-523-ABC study builds on the safety and clinical activity experience of previous studies that have evaluated ulixertinib as a novel targeted cancer treatment in cohorts of patients with specific genetic alterations and tumor histologies that result in aberrant MAPK pathway signaling. Early clinical data have demonstrated anti-tumor activity with ulixertinib treatment and have identified specific groups of patients for whom additional development is warranted.
Study identification
- NCT ID
- NCT04488003
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 104 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 7, 2021 (Actual)
- Primary completion
- Feb 15, 2023 (Actual)
- Completion
- May 23, 2023 (Actual)
- Last update posted
- Jun 4, 2024
2021 – 2023
United States locations
- U.S. sites
- 22
- U.S. states
- 18
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic | Phoenix | Arizona | 85054 | — |
| Hoag Memorial Hospital Presbyterian | Newport Beach | California | 92663 | — |
| Christiana Care Health Services / Helen F. Graham Cancer Center | Newark | Delaware | 19713 | — |
| Johns Hopkins Sibley Memorial Hospital | Washington D.C. | District of Columbia | 20016 | — |
| University of Florida | Gainesville | Florida | 32610 | — |
| Mayo Clinic | Jacksonville | Florida | 32224 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Metro-Minnesota Community Oncology Research Consortium (MMCORC) | Saint Louis Park | Minnesota | 55416 | — |
| Washington University School of Medicine - Siteman Cancer Center | St Louis | Missouri | 63110 | — |
| Columbia University Irving Medical Center | New York | New York | 10032 | — |
| Montefiore Medical Center | The Bronx | New York | 10461 | — |
| Duke University Medical Center / Duke Cancer Institute | Durham | North Carolina | 27710 | — |
| Kettering Cancer Center | Kettering | Ohio | 45429 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15213 | — |
| Avera Cancer Institute | Sioux Falls | South Dakota | 57105 | — |
| Tennessee Oncology, PLLC - Sarah Cannon (SCRI) | Nashville | Tennessee | 37203 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Virginia Cancer Specialists, PC | Fairfax | Virginia | 22031 | — |
| University of Washington/Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
| University of Wisconsin Clinical Science Center | Madison | Wisconsin | 53792 | — |
| Marshfield Medical Center | Marshfield | Wisconsin | 54449 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04488003, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 4, 2024 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04488003 live on ClinicalTrials.gov.